SUN-D Project SUN-D
  1. WHO. The global burden of disease: 2004 update.
  2. Kawakami N, Ono Y, Nakane Y, Nakamura Y, Tachimori H, Iwata N, et al. Twelve-month prevalence, severity, and treatment of common mental disorders in communities in Japan: The World Mental Health Japan 2002-2004 Survey. In: Kessler RC, Ustun TB, editors. World Mental Health Survey: Global Perspectives on the Epidemiology of Mental Disorders. New York: Cambridge University Press; 2008. p. 474-85.
  3. Arsenault-Lapierre G, Kim C, Turecki G. Psychiatric diagnoses in 3275 suicides: a meta-analysis. BMC Psychiatry. 2004;4:37.
  4. Cuijpers P, van Straten A, van Oppen P, Andersson G. Are psychological and pharmacologic interventions equally effective in the treatment of adult depressive disorders? A meta-analysis of comparative studies. J Clin Psychiatry. 2008 Nov;69(11):1675-85; quiz 839-41.
  5. Ciuna A, Andretta M, Corbari L, Levi D, Mirandola M, Sorio A, et al. Are we going to increase the use of antidepressants up to that of benzodiazepines? Eur J Clin Pharmacol. 2004 Nov;60(9):629-34.
  6. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry. 2000 Apr;157(4 Suppl):1-45.
  7. Clinical guidelines for the treatment of depressive disorders. Can J Psychiatry. 2001 Jun;46 Suppl 1:5S-90S.
  8. Qaseem A, Snow V, Denberg TD, Forciea MA, Owens DK. Using Second-Generation Antidepressants to Treat Depressive Disorders: A Clinical Practice Guideline from the American College of Physicians. Ann Intern Med. 2008 Nov 18;149(10):725-33.
  9. NICE. Depression: the treatment and management of depression in adults (partial update of NICE clinical guideline 23). London: National Institute for Clinical Excellence; 2009.
  10. 本橋伸高, editor. 気分障害の薬物治療アルゴリズム. 東京: じほう; 2003.
  11. Gartlehner G, Gaynes BN, Hansen RA, Thieda P, Deveaugh-Geiss A, Krebs EE, et al. Comparative Benefits and Harms of Second-Generation Antidepressants: Background Paper for the American College of Physicians. Ann Intern Med. 2008 Nov 18;149(10):734-50.
  12. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009 Jan 28;373:746-58.
  13. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006 Jan;163(1):28-40.
  14. Hirschfeld RM, Montgomery SA, Aguglia E, Amore M, Delgado PL, Gastpar M, et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry. 2002 Sep;63(9):826-37.
  15. Corruble E, Guelfi JD. Does increasing dose improve efficacy in patients with poor antidepressant response: a review. Acta Psychiatr Scand. 2000 May;101(5):343-8.
  16. Adli M, Baethge C, Heinz A, Langlitz N, Bauer M. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci. 2005 Dec;255(6):387-400.
  17. Ruhe HG, Huyser J, Swinkels JA, Schene AH. Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder: systematic review. Br J Psychiatry. 2006 Oct;189:309-16.
  18. Furukawa TA, Cipriani A, Barbui C, Geddes JR. Long-term treatment of depression with antidepressants: A systematic narrative review. Canadian Journal of Psychiatry Revue Canadienne de Psychiatrie. 2007;52(9):545-52.
  19. Ruhe HG, Huyser J, Swinkels JA, Schene AH. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry. 2006 Dec;67(12):1836-55.
  20. Ferreri M, Lavergne F, Berlin I, Payan C, Puech AJ. Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatr Scand. 2001 Jan;103(1):66-72.
  21. Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry. 2007 Jun;68(6):935-40.
  22. Aronson R, Offman HJ, Joffe RT, Naylor CD. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry. 1996 Sep;53(9):842-8.
  23. Papakostas GI, Shelton RC, Smith J, Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry. 2007 Jun;68(6):826-31.
  24. Licht RW, Qvitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology (Berl). 2002 May;161(2):143-51.
  25. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry. 2002 Jan 15;51(2):183-8.
  26. Whale R, Terao T, Cowen P, Freemantle N, Geddes J. Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: a systematic review. J Psychopharmacol. 2008 Oct 2.
  27. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006 Mar 23;354(12):1231-42.
  28. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006 Mar 23;354(12):1243-52.
  29. Papakostas GI, Charles D, Fava M. Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder. World J Biol Psychiatry. 2007 Jul 13:1-8.
  30. Fabre LF, Abuzzahab FS, Amin M, Claghorn JL, Mendels J, Petrie WM, et al. Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry. 1995 Nov 1;38(9):592-602.
  31. Cipriani A, La Ferla T, Furukawa TA, Signoretti A, Nakagawa A, Churchill R, et al. Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2009(2):CD006117.
  32. Blier P, Ward HE, Tremblay P, Laberge L, Hebert C, Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry. 2010 Mar;167(3):281-8.
  33. Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003 Feb 22;361(9358):653-61.
  34. Fujita A, Azuma H, Kitamura T, Takahasi K, Akechi T, Furukawa TA. Adequacy of continuation and maintenance treatments for major depression in Japan. J Psychopharmacol (Oxf). 2008 Jan 21;22(2):153-6.
  35. Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes A, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ. 2009;339:b2880.